PROCEPT BioRobotics Corporation (PRCT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $19.20 (-5.42% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PRCT ranks #505 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PRCT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 63.7%, and ROIC of -35.0%. By comparison, AORT (Artivion Inc.) holds a D- grade (40/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.10B) and ATEC (Alphatec Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
Per PRCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001588978), PROCEPT BioRobotics Corporation generated $308.1M in revenue (+37.2% YoY), -$95.6K in net income, and -$58.3M in free cash flow against $508.1M in total assets and $51.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.98 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 63.7% Gross Margin
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PRCT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.33) and Max Pain ($20.16) forces dealer call-delta covering toward $40.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
PROCEPT BioRobotics Corporation (PRCT) dropped -5.42% to $19.20, trading at 12% of its 52-week range ($16.67 – $38.11). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +37.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PRCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PRCT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, PROCEPT BioRobotics Corporation (PRCT) ranks #505 by composite RQD confidence (38/100, grade D-) and #345 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with PRCT at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRCT
ACTIVE
PROCEPT BioRobotics Corporation | D- | 38/100 | — | 63.7% | -35.0% | -5.42% | $1.10B | Benchmark Subject |
| AORT Artivion Inc. | D- | 40/100 | 117.0x | 64.4% | 4.5% | -3.67% | $1.10B | /aort-vs-prct → |
| ATEC Alphatec Holdings Inc. | E | 34/100 | — | 69.6% | -18.4% | -38.08% | $1.09B | /atec-vs-prct → |
| BVS Bioventus Inc. (Class A) | C- | 61/100 | 55.0x | 68.3% | 10.4% | -10.39% | $1.12B | /bvs-vs-prct → |
| SGP SpyGlass Pharma Inc. | D- | 43/100 | — | — | -35.0% | -0.83% | $1.08B | /sgp-vs-prct → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), PROCEPT BioRobotics Corporation (PRCT) reported GAAP revenue of $308.1M (+37.2% vs. FY2024 revenue of $224.5M , and +126.2% cumulative change since FY2023) , GAAP net income of -$95.6K, operating cash flow of -$49.0M, and free cash flow of -$58.3M (+43.7% YoY). On the balance sheet, PRCT closed FY2025 with $508.1M in total assets against $51.6M in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $308.1M | -$95.6K | -$49.0M | -$58.3M | $508.1M | $51.6M |
| FY2024 (FY) | 2024-12-31 | $224.5M | -$91.4K | -$99.2M | -$103.6M | $534.0M | $51.5M |
| FY2023 (FY) | 2023-12-31 | $136.2M | -$105.9K | -$108.0M | -$108.0M | — | — |
As of 2026-11-03, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $19.20 (-5.42% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PRCT ranks #505 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PRCT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 63.7%, and ROIC of -35.0%. By comparison, AORT (Artivion Inc.) holds a D- grade (40/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.10B) and ATEC (Alphatec Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
Per PRCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001588978), PROCEPT BioRobotics Corporation generated $308.1M in revenue (+37.2% YoY), -$95.6K in net income, and -$58.3M in free cash flow against $508.1M in total assets and $51.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PRCT last traded at $19.20 (-5.42% on volume of 856,501 shares), positioning the stock -0.67% below its 50-day simple moving average ($19.33) and -17.31% below its 200-day simple moving average ($23.22). Across its 52-week range of $16.67 to $38.11, PRCT sits at the 11.8% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($17.09 to $21.31).
Why PRCT Stock dropped -5.42% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PRCT scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Net effect for a prospective investor: the rating frames PRCT as a stock where liquidity and solvency are relatively protected, but operating losses, negative cash flow, and weak flow signals dominate the near-term case. Valuation tradeoffs center on the absence of positive earnings and cash flow metrics, which means the price of $20.30 cannot be tied to conventional earnings-based multiples from the source data.
PROCEPT BioRobotics Corporation (PRCT) is a NASDAQ-listed company classified in the Health Care sector and the Medical/Dental Instruments industry. The source data does not describe its specific products, customers, or revenue model. The FY 2025 and FY 2024 figures show reported revenue, but the mechanism of revenue generation is not described in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $308.1M | $-103.9M | $-0.1M | N/A | $-58.3M | $286.5M | $51.6M |
| FY 2024 | $224.5M | $-96.6M | $-0.1M | N/A | $-103.6M | $333.7M | $51.5M |
| FY 2023 | $136.2M | $-109.2M | $-0.1M | N/A | $-108.0M | N/A | N/A |
Per the SEC financials, revenue rose from $136.2M (FY 2023) to $308.1M (FY 2025), while operating losses remained large in each period. Gross margin is 63.7% and operating margin is -33.7%; net margin is 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 3.98, and the Piotroski F-Score is 4/9. Cash declined from $333.7M to $286.5M across FY 2024 to FY 2025, and debt was $51.6M in FY 2025.
Per the recent news feed, the items are:
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Analyst consensus, price targets, and holder data are not available in source data. The only analyst-related reference is the MarketBeat headline describing a "Hold" rating, which is a news wire item and not a structured consensus figure. Form 4 insider, 13F institutional, and Congressional trade detail is not available in source data beyond the aggregate pillar scores in the Roarable RQD rating.
Real-time company headlines, analyst actions, and sector developments for PROCEPT BioRobotics Corporation (PRCT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.
Welcome to the PRCT (PROCEPT BioRobotics Corporation) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PRCT, but look at what you are paying: current EV/EBITDA multiples with 63.7% gross margins. Unless PROCEPT BioRobotics Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PRCT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $20.30 (52-wk range $16.67 - $38.11), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).